Total Effective Xenoestrogen Burden in Serum Samples and Risk of Endometrial Cancer in the Spanish Screenwide Case-Control Study

Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)

Night work and endometrial cancer

Understanding risk factors for endometrial cancer in young women

Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.

Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503

Gasdermin-B (GSDMB) takes center stage in antibacterial defense, inflammatory diseases, and cancer

Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance

HuR (ELAVL1) Stabilizes SOX9 mRNA and Promotes Migration and Invasion in Breast Cancer Cells

Fatty acid amide hydrolase drives adult mammary gland development by promoting luminal cell differentiation

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation

Tumor-intrinsic perinuclear LOXL2: Prognostic relevance and relationship with YAP1 activation status in oral squamous cell carcinoma

Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management

Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors

Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations

Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Obesity, overweight and breast cancer: new clinical data and implications for practice

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.

Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase III Empower-cervical 1/GOG-3016/ENGOT-CX9 trial

Digital transformation of pathology - the European Society of Pathology expert opinion paper.

EPM2 AIP1 immunohistochemistry as a surrogate of promoter methylation analysis in endometrial carcinoma.

HER2 expression in a molecularly defined cohort of endometrial cancer patients: the spectrum study

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.

Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.

Implementing digital pathology: qualitative and financial insights from eight leading European laboratories.

Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma.

Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis.

The importance of the pseudocapsule in the management of uterine myoma: State of the art and expert recommendations.

The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexity.

The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology.

2023 FIGO staging system for endometrial cancer: The evolution of the revolution.

Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41/GEICO 69-O/ANITA phase III trial

Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.

Can morphology and immune infiltration predict the homologous recombination deficiency status in newly diagnosed high-grade serous ovarian carcinoma?

Current challenges and emerging tools in endometrial cancer diagnosis

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-OV25 trial

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

FIGO 2023 staging for endometrial cancer, when, if it is not now?

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

Histologic and molecular type changes in endometrial cancer recurrences in comparison with their corresponding primary tumors

Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2).

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: a subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Molecular classification improves preoperative risk assessment of endometrial cancer

Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium

Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis

Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO II study (GETHI2013-01)

Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread.

Perceptions of Controversies and Unresolved Issues in the 2014 FIGO Staging System for Endometrial Cancer: Survey Results From Members of the International Society of Gynecological Pathologists and International Gynecologic Cancer Society.

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (fap-il2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Postmenopausal onset of androgen excess: a diagnostic and therapeutic algorithm based on extensive clinical experience

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (PLD) in a real-world setting: a GEICO study

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-OV25

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)

Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape

Sprouty proteins are broad mediators of cellular senescence

Total Effective Xenoestrogen Burden in Serum Samples and Risk of Endometrial Cancer in the Spanish Screenwide Case-Control Study.